By Colin Kellaher 



  Bristol Myers Squibb Co. on Tuesday said its cancer drug Opdivo met key endpoints in a pair of phase 3 studies in cancers of the esophagus and stomach. 


  The New York biopharmaceutical company said a study evaluating Opdivo plus chemotherapy compared to chemotherapy alone met primary endpoints showing superior overall survival and progression-free survival as a first-line treatment for metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma. 


  The company said a separate study evaluating Opdivo as adjuvant therapy for patients with resected esophageal or gastroesophageal junction cancer met its primary endpoint of disease-free survival at a pre-specified interim analysis, adding that this is the second tumor, in addition to melanoma, where Opdivo has shown a benefit in the adjuvant setting. 


  Opdivo, which harnesses the body's own immune system to fight cancer, is currently approved in more than 65 countries across multiple cancers. 


  Write to Colin Kellaher at colin.kellaher@wsj.com